Business Context and Reporting Period
Company: Capricor Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 24, 2026
Principal Office: San Diego, California
Trading Symbol: CAPR (Nasdaq Global Select Market)
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding a regulatory event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material event reported is the extension of the Prescription Drug User Fee Act (PDUFA) target action date for the Company's Biologics License Application (BLA) for Deramiocel.
- Product: Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD).
- Previous Target Date: August 22, 2026.
- New Target Date: November 22, 2026.
- Reason for Extension: The FDA classified the submission as a major amendment, extending the review period by three months.
- Amendment Content: Includes 24-month open-label extension data from the pivotal Phase 3 HOPE-3 study and additional analyses.
- Strategic Focus: The request supports a refined proposed indication focused on upper limb function, which was the primary endpoint of the HOPE-3 study.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release indicating that the FDA continues its review of the Deramiocel BLA. The extension allows for the review of new data to support a specific indication regarding upper limb function.
Risks and Contingencies: The filing does not explicitly detail new risks beyond the inherent uncertainty of the regulatory review process. The extension implies that the FDA requires additional time to evaluate the major amendment and the refined indication.
Investor Verification Checklist
- Verify the specific details of the "refined proposed indication" for upper limb function in the full press release (Exhibit 99.1).
- Review the 24-month open-label extension data from the HOPE-3 study to assess the clinical support for the new indication.
- Monitor the Company's cash burn rate and liquidity position, as the extended review period may impact capital requirements prior to potential commercialization.
- Confirm if the extension affects the Company's intellectual property timelines or patent cliffs.